Published in Gene Therapy Weekly, December 17th, 2009
The trial is designed to investigate the safety and efficacy of ISF35 in combination with chemotherapy in patients with refractory and/or 17p-deleted CLL. Patients with this type of CLL currently have only limited therapeutic options.
Two patients have been treated so far in this trial, which is being conducted at the University of California, San Diego (UCSD) by Januario...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.